Affiliation:
1. Department of Pharmacy Practice, State University of New York at Buffalo, USA.
Abstract
Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. The use of lower doses, either as part of a combination regimen or as a result of dose reduction secondary to clinical intolerance, requires that a sensitive assay method be available for either traditional or population-based pharmacokinetic evaluations. We evaluated a radioimmunoassay technique with a standard curve range of 0 to 100 ng/ml in human plasma, urine, and cerebrospinal fluid and assessed its accuracy and precision for use in pharmacokinetic studies.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference18 articles.
1. Adams J. M. Shelton T. Grasela R. Hewitt M. DeRemer and G. Morse. 1995. Didanosine population pharmacokinetics: relationship between drug exposure and surrogate marker response abstr. 493 p. 146. In Abstracts of the Second National Conference on Human Retroviruses and Related Infections. American Society for Microbiology Washington D.C.
2. Clinical pharmacology of 2~,3~-dideoxyinosine in human immunodeficiency virus-infected children;Balis F. M.;J. Infect. Dis.,1992
3. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome;Barry M.;Br. J. Clin. Pharmacol.,1993
4. Bristol-Myers Squibb Laboratories. 1994. Videx Product Information. Bristol-Myers Squibb Laboratories New York.
5. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection;Collier A. C.;Ann. Intern. Med.,1993
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献